{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:54:12Z","timestamp":1789811652515,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA184228"],"award-info":[{"award-number":["CA184228"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Z-Alpha Therapeutics","award":["Z-Alpha Therapeutics"],"award-info":[{"award-number":["Z-Alpha Therapeutics"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07578-4","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:57:28Z","timestamp":1761814648000},"page":"2304-2313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [211At]YF2"],"prefix":"10.1007","volume":"53","author":[{"given":"Yutian","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truc T.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesan","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5456-0324","authenticated-orcid":false,"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"1","key":"7578_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","volume":"49","author":"MM Sathekge","year":"2021","unstructured":"Sathekge MM, et al. Global experience with PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;49(1):30\u201346. https:\/\/doi.org\/10.1007\/s00259-021-05434-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7578_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/pros.24137","volume":"81","author":"S Ballal","year":"2021","unstructured":"Ballal S, et al. 225Ac-PSMA\u2010617\u2010targeted alpha therapy for the treatment of metastatic castration\u2010resistant prostate cancer: A systematic review and meta\u2010analysis. Prostate. 2021;81(9):580\u201391. https:\/\/doi.org\/10.1002\/pros.24137.","journal-title":"Prostate"},{"issue":"10","key":"7578_CR3","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","volume":"49","author":"IO Lawal","year":"2022","unstructured":"Lawal IO, et al. Hematologic toxicity profile and efficacy of [225Ac] Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(10):3581\u201392. https:\/\/doi.org\/10.1007\/s00259-022-05778-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7578_CR4","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.178673.","journal-title":"J Nucl Med"},{"issue":"1 suppl","key":"7578_CR5","first-page":"S199","volume":"46","author":"DA Mulford","year":"2005","unstructured":"Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted \u03b1-particle therapy. J Nucl Med. 2005;46(1 suppl):S199\u2013204.","journal-title":"J Nucl Med"},{"issue":"7","key":"7578_CR6","doi-asserted-by":"publisher","first-page":"980","DOI":"10.2967\/jnumed.120.256388","volume":"62","author":"SR Banerjee","year":"2021","unstructured":"Banerjee SR, et al. Preclinical evaluation of 213Bi-and 225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2021;62(7):980\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.256388","journal-title":"J Nucl Med"},{"issue":"3","key":"7578_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, et al. An overview of targeted alpha therapy with225Actinium and213Bismuth. Curr Radiopharm. 2018;11(3):200\u20138. https:\/\/doi.org\/10.2174\/1874471011666180502104524.","journal-title":"Curr Radiopharm"},{"key":"7578_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","volume":"46","author":"JC Dos Santos","year":"2019","unstructured":"Dos Santos JC, et al. Development and dosimetry of203Pb\/212Pb-labelled PSMA ligands: bringing the lead into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46:1081\u201391. https:\/\/doi.org\/10.1007\/s00259-018-4220-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7578_CR9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1078-0432.CCR-19-2268","volume":"26","author":"S Hammer","year":"2020","unstructured":"Hammer S, et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin Cancer Res. 2020;26(8):1985\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2268.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7578_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1007\/s00259-023-06178-4","volume":"50","author":"R Chakravarty","year":"2023","unstructured":"Chakravarty R, et al. Astatine-211 for PSMA-targeted \u03b1-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology. Eur J Nucl Med Mol Imaging. 2023;50(7):1844\u20137. https:\/\/doi.org\/10.1007\/s00259-023-06178-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"7578_CR11","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","volume":"69","author":"H Song","year":"2009","unstructured":"Song H, et al. Radioimmunotherapy of breast cancer metastases with \u03b1-particle emitter225Ac: comparing efficacy with213Bi and90Y. Cancer Res. 2009;69(23):8941\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1828.","journal-title":"Cancer Res"},{"key":"7578_CR12","first-page":"31","volume":"98","author":"S Lemonick","year":"2020","unstructured":"Lemonick S. Astatine is a chemistry puzzle that shows anticancer promise. Chem Eng News. 2020;98:31.","journal-title":"Chem Eng News"},{"issue":"3","key":"7578_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00259-022-06016-z","volume":"50","author":"T Watabe","year":"2023","unstructured":"Watabe T, et al. Targeted \u03b1-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound. Eur J Nucl Med Mol Imaging. 2023;50(3):849\u201358. https:\/\/doi.org\/10.1007\/s00259-022-06016-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7578_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115667","volume":"25","author":"T Watabe","year":"2024","unstructured":"Watabe T, et al. Preclinical Evaluation of Biodistribution and Toxicity of [211At] PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer. Int J Mol Sci. 2024;25(11):5667. https:\/\/doi.org\/10.3390\/ijms25115667.","journal-title":"Int J Mol Sci"},{"key":"7578_CR15","doi-asserted-by":"publisher","unstructured":"Watabe T, et al. First-in-human SPECT\/CT imaging of [211At] PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer. EJNMMI. 2024;1\u20133. https:\/\/doi.org\/10.1007\/s00259-024-07017-w.","DOI":"10.1007\/s00259-024-07017-w"},{"issue":"21","key":"7578_CR16","doi-asserted-by":"publisher","first-page":"15846","DOI":"10.1021\/acs.jmedchem.1c01147","volume":"64","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, et al. Neopentyl glycol as a scaffold to provide radiohalogenated theranostic pairs of high in vivo stability. J Med Chem. 2021;64(21):15846\u201357. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01147.","journal-title":"J Med Chem"},{"issue":"1","key":"7578_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-024-00278-8","volume":"9","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, et al. In vivo stable211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure. EJNMMI Radiopharm Chem. 2024;9(1):48. https:\/\/doi.org\/10.1186\/s41181-024-00278-8.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"4","key":"7578_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2967\/jnumed.123.267043","volume":"65","author":"M El Fakiri","year":"2024","unstructured":"El Fakiri M, et al. Development and Preclinical Evaluation of [211At] PSAt-3-Ga: An Inhibitor for Targeted \u03b1-Therapy of Prostate Cancer. J Nucl Med. 2024;65(4):593\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.267043.","journal-title":"J Nucl Med"},{"issue":"10","key":"7578_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","volume":"57","author":"AP Kiess","year":"2016","unstructured":"Kiess AP et al. (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl) ureido)-pentanedioic acid for PSMA-targeted \u03b1-particle radiopharmaceutical therapy. J. Nucl. Med, 2016. 57(10): pp. 1569\u20131575. https:\/\/doi.org\/10.2967\/jnumed.116.174300","journal-title":"J Nucl Med"},{"key":"7578_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nucmedbio.2021.01.002","volume":"94","author":"G Vaidyanathan","year":"2021","unstructured":"Vaidyanathan G, et al. Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer. Nucl Med Biol. 2021;94:67\u201380. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.01.002.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"7578_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2967\/jnumed.121.262098","volume":"63","author":"RC Mease","year":"2022","unstructured":"Mease RC, et al. An improved211At-labeled agent for PSMA-targeted \u03b1-therapy. J Nucl Med. 2022;63(2):259\u201367. https:\/\/doi.org\/10.2967\/jnumed.121.262098.","journal-title":"J Nucl Med"},{"key":"7578_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108916","volume":"134","author":"Y Feng","year":"2024","unstructured":"Feng Y, et al. A third generation PSMA-targeted agent [211At] YF2: Synthesis and in vivo evaluation. Nucl Med Biol. 2024;134:108916. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108916.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"7578_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0969-8043(95)00285-5","volume":"47","author":"RH Larsen","year":"1996","unstructured":"Larsen RH, Wieland BW, Zalutsky MR. Evaluation of an internal cyclotron target for the production of211At via the209Bi (\u03b1, 2n)211At reaction. Appl Radiat Isot. 1996;47(2):135\u201343. https:\/\/doi.org\/10.1016\/0969-8043(95)00285-5.","journal-title":"Appl Radiat Isot"},{"key":"7578_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nucmedbio.2021.05.007","volume":"100","author":"Y Feng","year":"2021","unstructured":"Feng Y, Zalutsky MR. Production, purification and availability of211At: Near term steps towards global access. Nucl Med Biol. 2021;100:12\u201323. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.05.007.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"7578_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, et al. MIRD pamphlet 22 (abridged): radiobiology and dosimetry of \u03b1-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51(2):311\u201328. https:\/\/doi.org\/10.2967\/jnumed.108.058651.","journal-title":"J Nucl Med"},{"issue":"1","key":"7578_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2967\/jnumed.122.264071","volume":"64","author":"Y Feng","year":"2023","unstructured":"Feng Y, et al. Effective treatment of human breast carcinoma xenografts with single-dose211At-labeled anti-HER2 single-domain antibody fragment. J Nucl Med. 2023;64(1):124\u201330. https:\/\/doi.org\/10.2967\/jnumed.122.264071.","journal-title":"J Nucl Med"},{"issue":"3","key":"7578_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","volume":"93","author":"Y Benjamini","year":"2006","unstructured":"Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93(3):491\u2013507. https:\/\/doi.org\/10.1093\/biomet\/93.3.491.","journal-title":"Biometrika"},{"key":"7578_CR28","doi-asserted-by":"crossref","unstructured":"Machin D, Cheung YB, Parmar M. Survival analysis: a practical approach. John Wiley & Sons; 2006.","DOI":"10.1002\/0470034572"},{"key":"7578_CR29","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","volume":"46","author":"SR Banerjee","year":"2019","unstructured":"Banerjee SR, et al. 177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. EJNMMI. 2019;46:2545\u201357. https:\/\/doi.org\/10.1007\/s00259-019-04434-0.","journal-title":"EJNMMI"},{"issue":"1","key":"7578_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer L, et al. Long-term nephrotoxicity of177Lu-PSMA radioligand therapy. J Nucl Med. 2024;65(1):79\u201384. https:\/\/doi.org\/10.2967\/jnumed.123.265986.","journal-title":"J Nucl Med"},{"key":"7578_CR31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","volume":"48","author":"EA Ruigrok","year":"2021","unstructured":"Ruigrok EA, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339\u201350. https:\/\/doi.org\/10.1007\/s00259-020-05057-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7578_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MNM.0000000000001658","volume":"44","author":"MJ Uijen","year":"2023","unstructured":"Uijen MJ, et al. Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry. Nucl Med Commun. 2023;44(4):270. https:\/\/doi.org\/10.1097\/MNM.0000000000001658.","journal-title":"Nucl Med Commun"},{"issue":"11","key":"7578_CR33","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","volume":"49","author":"VJ Tschan","year":"2022","unstructured":"Tschan VJ, et al. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(11):3639\u201350. https:\/\/doi.org\/10.1007\/s00259-022-05837-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7578_CR34","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1007\/s00259-020-05150-w","volume":"48","author":"TM Kalidindi","year":"2021","unstructured":"Kalidindi TM, et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2021;48:2642\u201351. https:\/\/doi.org\/10.1007\/s00259-020-05150-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7578_CR35","doi-asserted-by":"publisher","first-page":"849","DOI":"10.7150\/thno.14744","volume":"6","author":"KLS Chatalic","year":"2016","unstructured":"Chatalic KLS, et al. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics. 2016;6(6):849\u201361. https:\/\/doi.org\/10.7150\/thno.14744.","journal-title":"Theranostics"},{"issue":"3","key":"7578_CR36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1021\/acsptsci.4c00637","volume":"8","author":"A Medvedeva","year":"2025","unstructured":"Medvedeva A, et al. Single-photon emission computer tomography imaging of prostate-specific membrane antigen (PSMA) expression in prostate cancer patients using a novel peptide-based probe [99mTc]Tc-BQ0413 with picomolar affinity to PSMA: a phase I\/II clinical study. ACS Pharmacol Transl Sci. 2025;8(3):736\u201347. https:\/\/doi.org\/10.1021\/acsptsci.4c00637.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"7","key":"7578_CR37","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.1c00994","volume":"19","author":"F Borgna","year":"2022","unstructured":"Borgna F, et al. Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy. Mol Pharm. 2022;19(7):2105\u201314. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00994.","journal-title":"Mol Pharm"},{"issue":"1","key":"7578_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2967\/jnumed.119.229393","volume":"61","author":"SR Banerjee","year":"2020","unstructured":"Banerjee SR, et al. Preclinical evaluation of203\/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61(1):80\u20138. https:\/\/doi.org\/10.2967\/jnumed.119.229393.","journal-title":"J Nucl Med"},{"key":"7578_CR39","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/2211-5463.12276","volume":"7","author":"T Knedlik","year":"2017","unstructured":"Knedlik T, et al. Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII. FEBS Open Bio. 2017;7:1362\u201378. https:\/\/doi.org\/10.1002\/2211-5463.12276.","journal-title":"FEBS Open Bio"},{"key":"7578_CR40","doi-asserted-by":"publisher","unstructured":"Huynh TT et al. Enhancing the therapeutic index of [211At]YF2 with iodo pseudo carrier: a simple strategy for reducing accumulation in kidneys, salivary and lacrimal glands. Nucl. Med. Biol., 2025. 146\u2013147: 109028 on line ahead of print https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109028","DOI":"10.1016\/j.nucmedbio.2025.109028"},{"issue":"5","key":"7578_CR41","doi-asserted-by":"publisher","first-page":"824","DOI":"10.2967\/jnumed.124.269111","volume":"66","author":"IE Wang","year":"2025","unstructured":"Wang IE, et al. Determining PSMA-617 mass and molar activity in pluvicto doses. J Nucl Med. 2025;66(5):824. https:\/\/doi.org\/10.2967\/jnumed.124.269111.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07578-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:42Z","timestamp":1771479522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07578-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7578"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07578-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved and performed following the guidelines of the Duke University Institutional Animal Care and Use Committee (IACUC) as described in Protocol A204-21-10 (2024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have consent to publish all the data in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Ganesan Vaidyanathan, Martin Pomper and Michael Zalutsky are co-inventors on a patent related to [\n                      211\n                      At]YF2, which has been licensed by Z-Alpha Therapeutics, Inc. Martin Pomper and Michael Zalutsky are co-founders of Z-Alpha Therapeutics and are minority shareholders via stock options. No other potential competing interests related to this work are reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}